| scholarly article | Q13442814 |
| P2093 | author name string | Karol Watson | |
| Weng Kee Wong | |||
| Daniel J Wallace | |||
| Nagesh Ragavendra | |||
| Michael Weisman | |||
| Brian Skaggs | |||
| Bevra H Hahn | |||
| Jennifer Grossman | |||
| John Fitzgerald | |||
| Elizabeth Volkmann | |||
| Maureen McMahon | |||
| Weiling Chen | |||
| George Karpouzas | |||
| Christina Charles-Schoeman | |||
| Alan Gorn | |||
| Lori Sahakian | |||
| P2860 | cites work | When good cholesterol turns bad | Q59029793 |
| High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules | Q71799260 | ||
| Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus | Q72607855 | ||
| Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 | ||
| Hopkins Lupus Cohort. 1999 update | Q73683618 | ||
| Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus | Q77909409 | ||
| Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus | Q79794986 | ||
| Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease | Q81342637 | ||
| Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA) | Q81526909 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Premature coronary-artery atherosclerosis in systemic lupus erythematosus | Q33974685 | ||
| Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 | ||
| The role of high-density lipoproteins in oxidation and inflammation | Q34423104 | ||
| Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells | Q34667731 | ||
| Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for V | Q34748094 | ||
| The human serum paraoxonase/arylesterase polymorphism. | Q35203636 | ||
| Structural modifications of HDL and functional consequences | Q36255533 | ||
| Formation of dysfunctional high-density lipoprotein by myeloperoxidase. | Q36266928 | ||
| Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients | Q36662681 | ||
| The paradox of dysfunctional high-density lipoprotein | Q36874842 | ||
| High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study | Q40070458 | ||
| Can dysfunctional HDL explain high coronary artery disease risk in South Asians? | Q40126351 | ||
| Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein | Q40343323 | ||
| The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture | Q41010478 | ||
| Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. | Q41219739 | ||
| Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. | Q41759689 | ||
| A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids | Q43694450 | ||
| Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo | Q44090023 | ||
| Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide | Q44114720 | ||
| Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome | Q44183283 | ||
| The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA). | Q44574510 | ||
| Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment | Q44668973 | ||
| HDL-inflammatory index correlates with poor outcome in hemodialysis patients | Q44737253 | ||
| Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. | Q46028181 | ||
| Prevention and treatment of atherosclerosis: a practitioner's guide for 2008. | Q46182524 | ||
| 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey | Q46193178 | ||
| Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis | Q46222728 | ||
| Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors | Q46232068 | ||
| Racial/Ethnic differences in subclinical atherosclerosis among adults with diabetes: the multiethnic study of atherosclerosis | Q46580933 | ||
| Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus | Q46724748 | ||
| Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus | Q46973423 | ||
| Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus | Q46982878 | ||
| Exposure to secondhand smoke and biomarkers of cardiovascular disease risk in never-smoking adults. | Q53571500 | ||
| Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. | Q54596156 | ||
| Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization | Q57398877 | ||
| Equivalence trials in SLE research: issues to consider | Q57420890 | ||
| P433 | issue | 8 | |
| P921 | main subject | atherosclerosis | Q12252367 |
| systemic lupus erythematosus | Q1485 | ||
| lipoprotein | Q28350 | ||
| P304 | page(s) | 2428-2437 | |
| P577 | publication date | 2009-08-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus | |
| P478 | volume | 60 |
| Q33931813 | A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. |
| Q37658524 | Accelerated atherosclerosis in SLE: mechanisms and prevention approaches |
| Q26820245 | Accelerated atherosclerosis in patients with SLE--mechanisms and management |
| Q35539166 | Accelerated vascular disease in systemic lupus erythematosus: role of macrophage |
| Q36330112 | Anti-apolipoprotein A-I antibodies and paraoxonase 1 activity in Systemic Lupus Erythematosus |
| Q35227165 | Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes |
| Q33887814 | Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus |
| Q41421002 | Association between cholesterol efflux capacity and coronary restenosis after successful stent implantation |
| Q39017583 | Association between ischemic heart disease and systemic lupus erythematosus-a large case-control study |
| Q34546651 | Autoimmune‐mediated reduction of high‐density lipoprotein–cholesterol and paraoxonase 1 activity in systemic lupus erythematosus–prone gld mice |
| Q37994309 | Biomarkers for systemic lupus erythematosus |
| Q36218375 | Cardiovascular disease and rheumatoid arthritis: an update |
| Q37330468 | Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. |
| Q27016554 | Cardiovascular disease in lupus: insights and updates |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q37829385 | Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy |
| Q36260399 | Cholesterol-Independent Suppression of Lymphocyte Activation, Autoimmunity, and Glomerulonephritis by Apolipoprotein A-I in Normocholesterolemic Lupus-Prone Mice |
| Q35349884 | Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis |
| Q92006099 | Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE |
| Q38162490 | Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus |
| Q38654271 | Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus? |
| Q26774903 | Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics |
| Q34779002 | Dysfunctional high-density lipoproteins in children with chronic kidney disease |
| Q34137840 | Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production |
| Q35029916 | Dyslipidaemia in rheumatological autoimmune diseases |
| Q42734507 | Expanding the therapeutic frontier in atherosclerosis |
| Q36050857 | Fatigue in systemic lupus erythematosus |
| Q36031383 | Frequency, clinical implication and prognostic value of lymphopenia in systemic lupus erythematosus: case-control study |
| Q37684531 | Glycomic analysis of high density lipoprotein shows a highly sialylated particle |
| Q47761129 | HDL Cholesterol Efflux is Impaired in Older Patients with Early Sepsis: A Subanalysis of a Prospective Pilot Study |
| Q37838234 | HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms |
| Q35138355 | High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids |
| Q64245247 | High-Density Lipoprotein Function and Dysfunction in Health and Disease |
| Q36714306 | High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus. |
| Q36484474 | High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus |
| Q55515189 | Impact of Dietary Cholesterol on the Pathophysiology of Infectious and Autoimmune Disease. |
| Q37782589 | Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coin |
| Q34104339 | Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis |
| Q39600465 | Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus |
| Q90390566 | LOX-1: A potential driver of cardiovascular risk in SLE patients |
| Q45162401 | Leptin, adiponectin and vascular stiffness parameters in women with systemic lupus erythematosus |
| Q64946734 | Linking CD1-Restricted T Cells With Autoimmunity and Dyslipidemia: Lipid Levels Matter. |
| Q33784693 | Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus |
| Q51560974 | Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity. |
| Q33730536 | Management of cardiovascular complications in systemic lupus erythematosus |
| Q34343906 | Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus |
| Q51119389 | Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis. |
| Q34098294 | Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus |
| Q50052184 | Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. |
| Q36359128 | Overweight Is a Major Contributor to Atherosclerosis in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Cross-Sectional Controlled Study |
| Q35615662 | Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis |
| Q38230699 | Pathogenesis and treatment of atherosclerosis in lupus |
| Q51366906 | Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial. |
| Q36903365 | Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus |
| Q33387473 | Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study |
| Q38149850 | Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand? |
| Q33704086 | Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound |
| Q35174611 | Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin |
| Q43242936 | Reproductive immunology: current status and future directions (part I). |
| Q36299359 | Risk of Peripheral Arterial Occlusive Disease in Patients With Systemic Lupus Erythematosus: A Nationwide Population-Based Cohort Study |
| Q100503949 | Suppression of inflammatory arthritis in human serum paraoxonase 1 transgenic mice |
| Q37033345 | Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention |
| Q35530248 | Systemic lupus erythematosus and thrombosis |
| Q53194239 | Systemic lupus erythematosus risk factors for coronary artery calcifications. |
| Q50848358 | Systemic lupus erythematosus. |
| Q36712941 | Taming lupus-a new understanding of pathogenesis is leading to clinical advances |
| Q28069667 | The Sphinx's riddle: cardiovascular involvement in autoimmune rheumatic disease |
| Q35169351 | The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus |
| Q50417164 | The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity |
| Q34027495 | Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis |
| Q36139902 | Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis |
| Q39150632 | Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. |
| Q27005906 | Unmet medical needs in systemic lupus erythematosus |
| Q38591752 | Why are kids with lupus at an increased risk of cardiovascular disease? |
Search more.